Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Yap

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
JAMA|May 17, 2022
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics GuidelinesSamantha Cruz Rivera, Olalekan Lee Aiyegbusi, Jonathan Ives, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastomaCrescens Tiu, Wing Yau, Diogo Silva, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Eclinicalmedicine|October 10, 2024
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtableChristina Yap, Olalekan Lee Aiyegbusi, Emily Alger, et al.
Trials|September 6, 2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials unitsSharon B Love, Fay Cafferty, Claire Snowdon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
JAMA|May 17, 2022
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics GuidelinesSamantha Cruz Rivera, Olalekan Lee Aiyegbusi, Jonathan Ives, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2026
Phase I trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway immune responses in solid tumors and refractory glioblastomaCrescens Tiu, Wing Yau, Diogo Silva, et al.
European Urology Oncology|June 26, 2025
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular SubtypesPasquale Rescigno, Maria Dolores Fenor de la Maza, Holly Tovey, et al.
Eclinicalmedicine|January 29, 2025
CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trialsJan Rekowski, Christina Guo, Olga Solovyeva, et al.
Eclinicalmedicine|January 29, 2025
SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocolsMoreno Ursino, Guillermo Villacampa, Jan Rekowski, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Pageof 9